Anzemet (Dolasetron Mesylate Monohydrate) - Summary

ANZEMET SUMMARY

ANZEMET (dolasetron mesylate) is an antinauseant and antiemetic agent.

ANZEMET Tablets are indicated for:

1. the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses;
2. the prevention of postoperative nausea and vomiting.

ANZEMET NEWS HIGHLIGHTS

Media Articles Related to Anzemet (Dolasetron)

dolasetron-oral, Anzemet
Source: MedicineNet Antiemetics Specialty [2005.03.02]

FDA Approves ALOXI(R) (Palonosetron HCl) Capsules For Prevention Of Acute Chemotherapy Induced Nausea And Vomiting
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2008.08.24]

Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2008.04.29]

more>>

Published Studies Related to Anzemet (Dolasetron)

Inspired oxygen fraction of 0.8 compared with 0.4 does not further reduce postoperative nausea and vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy. [2006.11]

Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. [2006.04]

Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. [2005.11]

Dolasetron versus ondansetron for the treatment of postoperative nausea and vomiting. [2005.02]

Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting. [2004.08]

more>>

Clinical Trials Related to Anzemet (Dolasetron)

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects [Completed]

Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy [Active, not recruiting]

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer [Completed]

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas [Active, not recruiting]

more>>